1YI Stock Overview
A clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Purple Biotech Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪6.12 |
| 52 Week High | ₪29.80 |
| 52 Week Low | ₪5.44 |
| Beta | 0.41 |
| 11 Month Change | -11.05% |
| 3 Month Change | -15.93% |
| 1 Year Change | -70.86% |
| 33 Year Change | -91.82% |
| 5 Year Change | -95.28% |
| Change since IPO | -97.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1YI | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.0% | 1.0% |
| 1Y | -70.9% | -15.0% | 11.2% |
Return vs Industry: 1YI underperformed the German Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: 1YI underperformed the German Market which returned 11.2% over the past year.
Price Volatility
| 1YI volatility | |
|---|---|
| 1YI Average Weekly Movement | 14.1% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1YI's share price has been volatile over the past 3 months.
Volatility Over Time: 1YI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20 | Gil Efron | purple-biotech.com |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
Purple Biotech Ltd Fundamentals Summary
| 1YI fundamental statistics | |
|---|---|
| Market cap | €9.25m |
| Earnings (TTM) | -€14.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 1YI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1YI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$196.00k |
| Gross Profit | -US$196.00k |
| Other Expenses | US$15.84m |
| Earnings | -US$16.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1YI perform over the long term?
See historical performance and comparison